19.10.2020 • NewsBrenntag

Brenntag Buys Italy’s Comelt

Brenntag has agreed to buy Italian activated carbon company Comelt and its subsidiary Aquadepur for an undisclosed sum.

Comelt processes, markets and distributes activated and re-activated carbon for uses that include filtering water and purifying air and flue gas. The business generated sales of approximately €31 million in the financial year 2019.

The acquisition includes warehouses and a laboratory in northern Italy. The warehouses are located in Cernusco sul Naviglio, Milan; Cairo Montenotte, Savona; and Casirate d’Adda, Bergamo. Comelt also owns an activated carbon washing plant as well as a carbon reactivation facility.

“We expect an increasing demand for activated carbon for years to come due to the stricter purity standards for air and water quality,” said Brenntag Group managing director, mergers & acquisitions, Anthony Gerace. “The acquisition of Comelt will strengthen our ability to assist our customers with meeting their sustainability objectives. This is an opportunity for Brenntag to increase our market share in these important high growth and significant market segments in Italy as well as in other European countries.”

The transaction is expected to close in the final quarter of 2020, subject to the usual conditions and regulatory approvals.

Author: Elaine Burridge, Freelance Journalist

 

Foto: Brenntag
Foto: Brenntag

Company

Logo:

Brenntag SE

Messeallee 11
45131 Essen
Germany

Company contact







Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read